|
FY2026
12 months to Jan 31, 2026
|
FY2025
12 months to Jan 31, 2025
|
FY2024
12 months to Jan 31, 2024
|
FY2023
12 months to Jan 31, 2023
|
FY2022
12 months to Jan 31, 2022
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||
| Net income (loss) available to common shareholders | |||||
| Adjustments to reconcile net income (loss) to net cash used in operating activities: | |||||
| Depreciation | |||||
| Stock based compensation | |||||
| Amortization of debt discounts | |||||
| Gain on change in fair value of derivative liabilities | |||||
| Loss on settlement of liabilities | |||||
| Changes in assets and liabilities: | |||||
| Prepaid expenses | |||||
| Accounts payable and accrued expenses | |||||
| Accrued expenses to related party | |||||
| Cash flows used in operating activities: | |||||
| Cash flows from financing activities: | |||||
| Proceeds from advances, related party | |||||
| Repayments of advances, related party | |||||
| Proceeds from advances | |||||
| Repayments of advances | |||||
| Repayments of notes payable | |||||
| Cash advances | |||||
| Proceeds from notes payable, related party | |||||
| Repayments of notes payable, related party | |||||
| Proceeds from convertible promissory notes | |||||
| Repayments of convertible promissory notes | |||||
| Proceeds from the issuance of common stock and warrants in a private placement | |||||
| Receipt of subscription receivable | |||||
| Net cash provided by financing activities | |||||
| Increase (decrease) in cash and cash equivalents | |||||
| Cash and cash equivalents, beginning of period | |||||
| Cash and cash equivalents, end of period | |||||
| Supplemental disclosure of cash flow information: | |||||
| Interest paid | |||||
| Supplemental disclosure of non-cash items: | |||||
| Resolution of derivative liabilities due to debt conversions and untainted warrants | |||||
| Shares issued for conversion of debt and interest | |||||
| Expenses paid by related party on behalf of the Company | |||||
| Prepaid insurance financed with note payable | |||||
| Cashless exercise of warrants | |||||
| Settlement of subscription and interest receivable | |||||
| Issuance of common stock and warrants for equipment | |||||
| Issuance of common stock and warrants for settlement of liabilities | |||||
| Issuance of common stock and warrants in private placement for settlement of liabilities | |||||
| Resolution of derivative liabilities due to debt conversions | |||||
| Debt discounts due to derivative liabilities | |||||
| Common stock issued for conversion of debt and interest | |||||
| Reclass of APIC to derivative liabilities for tainted warrants | |||||
| Shares issued for deferred financing costs | |||||
| Issuance of common stock and warrants in private placement | |||||
| Reclassification of deferred financing costs to equity | |||||
Loading...